Menaquinone-7 (Vitamin K2-7)
(Synonyms: 维生素K2(35),Vitamin K2-7; Vitamin K2(35); Vitamin MK-7) 目录号 : GC32498
Menaquinone-7 (Vitamin K2-7), a highly valuable member of the vitamin K series, has significant effects on preventing osteoporosis and cardiovascular disease besides its positive effects on blood coagulation.
Cas No.:2124-57-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
Primary astrocytes |
|
Preparation Method |
The astrocytes were divided into the pretreatment group and no pretreatment group. In the pretreatment group, the astrocytes were pretreated for 30 h with Menaquinone-7 concentrations (10, 50, 100, and 150 µM) with 10% FBS in DMEM/F12. They were then maintained under either normoxic (5% CO2 /95% air, 37°C) or hypoxic (5% CO2 /95% N2, 37°C) conditions for different time intervals. The culture medium was changed to glucose-free Dulbecco's Modified Eagle's Medium without FBS before incubating the astrocytes under hypoxic onditions. Hypoxia was induced by incubating the astrocytes using the hypoxic workstation. |
|
Reaction Conditions |
10, 50, 100, and 150 µM for 30 h |
|
Applications |
Pretreatment with Menaquinone-7 did not cause these apparent morphological alterations in these astrocytes. the morphological alterations in astrocytes pretreated with Menaquinone-7 were reduced and the number of adherent astrocytes significantly increased under hypoxic conditions. |
| Animal experiment [2]: | |
|
Animal models |
4-week-old C57BL/6J male mice |
|
Preparation Method |
The AIN-93G diets consisted of a normal diet (N), normal diet + vitamin K1 (N-K1), normal diet + Menaquinone-7 (N-K2), 45% high-fat diet (HF), 45% high-fat diet + vitamin K1 (HF-K1), and a 45% high-fat diet + Menaquinone-7 (HF-K2). The vitamin K1 and Menaquinone-7 contents were 200 mg/1,000 g, and the diet was provided in pellet form. Food intake amount was measured every other day. Body weight was measured once a week, and the food efficiency ratio (FER) was calculated by dividing the increased body weight from day1 to the final day by the food intake amount during the experiment period. |
|
Dosage form |
200 mg/1,000 g fed with AIN-93G diets |
|
Applications |
Osteocalcin (OC) level of HF groups which were supplemented with vitamin K1 or Menaquinone-7, was higher than that in the HF diet-only group , type I collagen Ctelopeptide (CTx) was lower in the vitamin K-supplemented HF groups than the HF diet-only group. |
|
References: [1]: Yang R Y, Pan J Y, Chen Y, et al. Menaquinone-7 protects astrocytes by regulating mitochondrial function and inflammatory response under hypoxic conditions[J]. Eur. Rev. Med. Pharmacol. Sci, 2020, 24: 10181-10193. | |
Menaquinone-7 (Vitamin K2-7), a highly valuable member of the vitamin K series, has significant effects on preventing osteoporosis and cardiovascular disease besides its positive effects on blood coagulation [1].
Menaquinone-7 (10 µM) treated MC3T3E1 cells for 24, 48, 96 and 240 h, no statistical differences at 24, 48 and 96 h, the growth of MK-7 treated cells was significantly suppressed at 240 h. Menaquinone-7 increased osteocalcin, osteoprotegerin, and RANKL mRNA expression in osteoblastic MC3T3E cells [2]. After 24 h of Menaquinone-7 administration, genes upregulated by Menaquinone-7 included tenascin C and BMP2. Genes downregulated by Menaquinone-7 administration included biglycan and butyrophilin [3]. Menaquinone-7 (1 µM) increases alkaline phosphatase activity and calcium content in femoral-metaphyseal tissues isolated from normal and skeletal-unloaded rats [4]. Menaquinone-7 (10 µM) promotes osteoblast maturation thereby increasing osteogenic differentiation [5].
Menaquinone-7 increased The bone formation marker osteocalcin (OC), which is the bone formation marker [6]. Menaquinone-7 (200 mg/1,000 g fed with diets) supplementation decreases the bone resorption index and increases the bone formation index, balancing bone metabolism, and is considered to prevent bone loss [6].
References:
[1]. Mahdinia E, Demirci A, Berenjian A. Production and application of menaquinone-7 (vitamin K2): a new perspective[J]. World Journal of Microbiology and Biotechnology, 2017, 33(1): 1-7.
[2]. Katsuyama H, Otsuki T, Tomita M, et al. Menaquinone-7 regulates the expressions of osteocalcin, OPG, RANKL and RANK in osteoblastic MC3T3E1 cells[J]. International journal of molecular medicine, 2005, 15(2): 231-236.
[3]. Katsuyama H, Saijoh K, Otsuki T, et al. Menaquinone-7 regulates gene expression in osteoblastic MC3T3E1 cells[J]. International journal of molecular medicine, 2007, 19(2): 279-284.
[4]. Ehara Y, Takahashi H, Hanahisa Y, et al. Effect of vitamin K2 (menaquinone-7) on bone metabolism in the femoral-metaphyseal tissues of normal and skeletal-unloaded rats: enhancement with zinc[J]. Research in experimental medicine, 1996, 196(1): 171-178.
[5]. Akbulut A C, Wasilewski G B, Rapp N, et al. Menaquinone-7 supplementation improves osteogenesis in pluripotent stem cell derived mesenchymal stem cells[J]. Frontiers in cell and developmental biology, 2021, 8: 618760.
[6]. Brown J P, Malaval L, Chapuy M C, et al. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis[J]. The Lancet, 1984, 323(8386): 1091-1093.
| Cas No. | 2124-57-4 | SDF | |
| 别名 | 维生素K2(35),Vitamin K2-7; Vitamin K2(35); Vitamin MK-7 | ||
| Canonical SMILES | O=C1C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)\C)=C(C)C(C2=C1C=CC=C2)=O | ||
| 分子式 | C46H64O2 | 分子量 | 649 |
| 溶解度 | DMSO : 5 mg/mL (7.70 mM);Water : < 0.1 mg/mL (insoluble) | 储存条件 | Store at -20°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.5408 mL | 7.7042 mL | 15.4083 mL |
| 5 mM | 0.3082 mL | 1.5408 mL | 3.0817 mL |
| 10 mM | 0.1541 mL | 0.7704 mL | 1.5408 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Molecular Pathways and Roles for Vitamin K2-7 as a Health-Beneficial Nutraceutical: Challenges and Opportunities
Front Pharmacol 2022 Jun 14;13:896920.PMID:35774605DOI:10.3389/fphar.2022.896920.
Vitamin K2-7, also known as Menaquinone-7 (MK-7) is a form of vitamin K that has health-beneficial effects in osteoporosis, cardiovascular disease, inflammation, cancer, Alzheimer's disease, diabetes and peripheral neuropathy. Compared to vitamin K1 (phylloquinone), K2-7 is absorbed more readily and is more bioavailable. Clinical studies have unequivocally demonstrated the utility of Vitamin K2-7 supplementation in ameliorating peripheral neuropathy, reducing bone fracture risk and improving cardiovascular health. We examine how undercarboxylated osteocalcin (ucOC) and matrix Gla protein (ucMGP) are converted to carboxylated forms (cOC and cMGP respectively) by K2-7 acting as a cofactor, thus facilitating the deposition of calcium in bones and preventing vascular calcification. K2-7 is beneficial in managing bone loss because it upregulates osteoprotegerin which is a decoy receptor for RANK ligand (RANKL) thus inhibiting bone resorption. We also review the evidence for the health-beneficial outcomes of K2-7 in diabetes, peripheral neuropathy and Alzheimer's disease. In addition, we discuss the K2-7-mediated suppression of growth in cancer cells via cell-cycle arrest, autophagy and apoptosis. The mechanistic basis for the disease-modulating effects of K2-7 is mediated through various signal transduction pathways such as PI3K/AKT, MAP Kinase, JAK/STAT, NF-κB, etc. Interestingly, K2-7 is also responsible for suppression of proinflammatory mediators such as IL-1α, IL-1β and TNF-α. We elucidate various genes modulated by K2-7 as well as the clinical pharmacometrics of Vitamin K2-7 including K2-7-mediated pharmacokinetics/pharmacodynamics (PK/PD). Further, we discuss the current status of clinical trials on K2-7 that shed light on dosing strategies for maximum health benefits. Taken together, this is a synthetic review that delineates the health-beneficial effects of K2-7 in a clinical setting, highlights the molecular basis for these effects, elucidates the clinical pharmacokinetics of K2-7, and underscores the need for K2-7 supplementation in the global diet.
Production of menaquinone (vitamin K2)-7 by Bacillus subtilis
J Biosci Bioeng 2001;91(1):16-20.PMID:16232939DOI:10.1263/jbb.91.16.
Menaquinone-7 (MK-7) is a highly bioactive homologue of vitamin K. We obtained a diphenylamine-resistant mutant strain D200-41 from Bacillus subtilis strain MH-1 which was isolated from fermented soybeans, natto. The mutant strain exhibited decreased production of MK-6. Using strain D200-41, efficient production of MK-7 was achieved. We found that, compared with an agitated and aerated culture, production of MK-7 was increased by static culture. The sporulation of the cells progressed more slowly in a static culture than in an agitated culture. The maximum concentration of MK reached about 60 mg/l in a medium containing 10% soybean extract, 5% glycerol, 0.5% yeast extract and 0.05% K2HPO4 (pH 7.3) when D200-41 cells as well as MH-1 cells were statically cultured at 45 degrees C for 5 d after being cultured with shaking at 37 degrees C for 1 d.